Results 21 to 30 of about 455 (167)

Kaposi's Varicelliform Eruption: A Potentially Life-Threatening Complication of Atopic Dermatitis. [PDF]

open access: yesEur J Case Rep Intern Med
Introduction: Kaposi’s varicelliform eruption (KVE), also known as eczema herpeticum or eczema vaccinatum, is an acute dermatosis that affects patients with chronic dermatopathies.
Martín-Galache M   +6 more
europepmc   +3 more sources

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 37, Issue 9, Page 1871-1880, September 2023., 2023
Abstract Background Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease with different clinical phenotypes based on factors such as age, race, comorbidities, and clinical signs and symptoms. The effect of these factors on therapeutic responses in AD has only been scarcely studied and not for upadacitinib.
J. P. Thyssen   +16 more
wiley   +1 more source

Kaposi varicelliform eruption caused by varicella virus in a case of tinea corporis et cruris

open access: yesClinical Dermatology Review, 2020
Kaposi varicelliform eruption (KVE) is a disseminated vesiculopustular lesion occurring over a preexisting cutaneous lesion. Although initially thought to be caused by herpes virus 1 and 2, other viruses have also been known to provoke the disease. There
Mudita Gupta   +2 more
doaj   +1 more source

Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy

open access: yesThe Journal of Dermatology, Volume 50, Issue 7, Page e198-e205, July 2023., 2023
Abstract Hydroa vacciniforme lymphoproliferative disorder (HV‐LPD) and severe mosquito bite allergy (SMBA) are both cutaneous forms of Epstein–Barr virus (EBV)‐associated T/natural killer (NK) cell LPDs and are closely related to chronic active EBV disease (CAEBV) and EBV‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH).
Yoji Hirai   +9 more
wiley   +1 more source

Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance

open access: yesJournal of Cutaneous Immunology and Allergy, Volume 6, Issue 3, Page 78-87, June 2023., 2023
Patients with moderate‐to‐severe atopic dermatitis (AD) who initiated treatment with dupilumab between July 2019 and June 2020 in Japan were enrolled in this post‐marketing surveillance. At the interim data cut‐off, dupilumab appeared to be a safe and effective treatment option for patients aged ≥ 15 years with moderate‐to‐severe AD in routine clinical
Hidehisa Saeki   +3 more
wiley   +1 more source

Eczema herpeticum and impetigo herpetiformis, is there a link?

open access: yesJEADV Clinical Practice, Volume 2, Issue 1, Page 140-143, March 2023., 2023
Abstract Impetigo herpetiformis (IH) is a rare variant of pustular psoriasis with typical onset during the third trimester of pregnancy; it is characterized by erythematous plaques lined with sterile pustules and sometimes there may be systemic involvement.
Fortunato Cassalia   +4 more
wiley   +1 more source

Recent advance in management of herpes simplex in Japan

open access: yesThe Journal of Dermatology, Volume 50, Issue 3, Page 299-304, March 2023., 2023
Abstract Herpes simplex, a common infection caused by the herpes simplex virus (HSV), is transmitted through contact of the skin/mucous membrane and establishes latency in the sensory ganglia for the rest of the life of the host. HSV occasionally reactivates and forms blisters around the lips or genitalia in some patients. Repeated overt symptoms, and,
Shinichi Imafuku
wiley   +1 more source

Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate‐to‐severe atopic dermatitis: Two‐year data from the ADDRESS‐J disease registry

open access: yesThe Journal of Dermatology, Volume 49, Issue 9, Page 903-911, September 2022., 2022
Abstract Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease with a high disease burden, is one of the most common dermatological conditions in Japan. Herein, we report the disease profiles and current AD treatment during 2‐year management of Japanese adults with moderate‐to‐severe AD.
Norito Katoh   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy